Charles Richter King
Geen lopende functies
Profiel
Charles Richter King was Senior Vice President of Research for GenVec, Inc. until April 15, 2009.
He joined GenVec in 1998.
Previously, he was Vice President of New Product Research for GenVec and Director of Drug Discovery for Oncologix.
Dr. King directed an experienced research group at the Georgetown University Medical School's Lombardi Cancer Research Center in Washington, DC, where he served as Associate Professor with the University's Department of Biochemistry.
He received a PhD in Biochemistry from Johns Hopkins University.
Eerdere bekende functies van Charles Richter King
| Bedrijven | Functie | Einde |
|---|---|---|
| GENVEC INC | Hoofd Techniek/Wetenschap/O&O | 15-04-2009 |
| AGENUS INC. | Directeur/Bestuurslid | - |
Opleiding van Charles Richter King
| The Johns Hopkins University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AGENUS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
